EIF4EBP2抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P08080(EIF4EBP2 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P08080(EIF4EBP2 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

The EIF4EBP2 antibody is a tool used to study the eukaryotic translation initiation factor 4E-binding protein 2 (EIF4EBP2), a key regulator of cap-dependent translation. EIF4EBP2. also known as 4E-BP2. belongs to a family of small inhibitory proteins (including 4E-BP1 and 4E-BP3) that bind to the mRNA cap-binding protein eIF4E, thereby blocking its interaction with eIF4G and suppressing the assembly of the translation initiation complex. This regulation is primarily controlled by the mTOR (mechanistic target of rapamycin) signaling pathway, which phosphorylates EIF4EBP2 to release eIF4E, enabling protein synthesis. Dysregulation of this pathway is implicated in cancers, metabolic disorders, and neurodegenerative diseases.

EIF4EBP2 antibodies are widely used in research to detect protein expression, phosphorylation status, and interactions with eIF4E in various biological contexts. They are essential for techniques like Western blotting, immunohistochemistry, and immunoprecipitation. Commercially available antibodies are typically raised against specific epitopes, such as the phosphorylated Thr70 residue (a key mTOR target) or the full-length protein. Validation often involves knockout cell lines or phosphorylation-specific assays to ensure specificity. Studying EIF4EBP2 helps elucidate mechanisms of translational control in cellular stress, growth, and disease, particularly in cancer research where mTOR hyperactivity is common.